7. 大脳皮質基底核変性症 Disease details / Clinical trials / Drug dev / DR info

11C-PIB
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036956   Japan
      2019   -   JPRN-UMIN000036908   Japan
11C-raclopride
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036952   Japan
13c6 leucine
   Washington University School of Medicine
      2017   -   NCT03545126   United States
18F-AV-1451
   Skåne University Hospital, Region Skåne
      2014   Phase 2   EUCTR2014-000422-38-SE   Sweden
18F-FDG
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036908   Japan
18F-RO6958948
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden
ABBV-8e12
   AbbVie
      2018   -   NCT03744546   -
AL-108
   University of California, San Francisco
      2010   Phase 1   NCT01056965   United States
ANTI-parkinson medication
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States
Apomorphine
   Fondation Ophtalmologique Adolphe de Rothschild
      2018   -   NCT04786158   France
BIIB092
   University of California, San Francisco
      2018   Phase 1   NCT03658135   United States
Botulinum toxin type A
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
Brain PET scan
   Avid Radiopharmaceuticals
      2014   Phase 1   NCT02167594   United States
Davunetide
   University of California, San Francisco
      2010   Phase 1   NCT01056965   United States
Deep brain stimulation
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States
Dopamine
   Juntendo University school of Medicine Department of Diagnosis, Prevention and Treatment of Dementia
      2014   -   JPRN-UMIN000014098   Japan
Elecsys (roche) abeta42, ttau and ptau
   Skane University Hospital
      2017   -   NCT03174938   Sweden
F-18
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden
Fasudil
   Woolsey Pharmaceuticals
      2021   Phase 2   NCT04734379   United States
FDG-PET
   Itoh Yoshiaki
      2019   -   JPRN-jRCTs051180214   -
Flortaucipir F18
   Avid Radiopharmaceuticals
      2014   Phase 1   NCT02167594   United States
Flutemetamol
   Itoh Yoshiaki
      2019   -   JPRN-jRCTs051180214   -
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden
Flutemetamol F18 injection
   Skane University Hospital
      2017   -   NCT03174938   Sweden
Glycerol phenylbutyrate
   Klinikum rechts der Isar der Technischen Universität München
      2023   Phase 2   EUCTR2022-002988-30-DE   Germany
Injection
   Kagawa University
      2021   -   JPRN-UMIN000043737   Japan
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden
   Skåne University Hospital, Region Skåne
      2014   Phase 2   EUCTR2014-000422-38-SE   Sweden
Lithium
   Westat
      2008   Phase 1/Phase 2   NCT00703677   United Kingdom;United States
Lumipulse (fujirebio) abeta42, ttau and ptau
   Skane University Hospital
      2017   -   NCT03174938   Sweden
Nicotinamide riboside
   Haukeland University Hospital
      2024   Phase 2   NCT06162013   Norway
NT 101
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
PET/CT
   Kagawa University
      2021   -   JPRN-UMIN000043737   Japan
Ravicti
   Klinikum rechts der Isar der Technischen Universität München
      2023   Phase 2   EUCTR2022-002988-30-DE   Germany
Ravicti 1.1 G/ML
   Technical University of Munich
      2023   Phase 2   NCT05983588   Germany
THK-5351
   Kagawa University
      2021   -   JPRN-UMIN000043737   Japan
   Nagoya University Department of Neurology
      2015   -   JPRN-UMIN000018496   Japan
THK5351
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036956   Japan
   Tohoku University
      2017   -   JPRN-UMIN000021819   Japan
TPI 287 2 MG/M2
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States
TPI-287 20 MG/M2
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States
TPI-287 6.3 MG/M2
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States
Vizamyl
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden
Xeomin
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States